Skip to main content
Erschienen in: International Cancer Conference Journal 2/2021

09.01.2021 | Case report

Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma

verfasst von: Hiroshi Yaegashi, Yuki Kato, Takahiro Nohara, Kouji Izumi, Yoshifumi Kadono, Tohru Miyagi, Takao Nakashima, Kaori Yoshimura, Yasunori Sato, Kenichi Harada, Atsushi Mizokami

Erschienen in: International Cancer Conference Journal | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Histiocytic sarcoma is considered an extremely rare condition. We herein report on a case of histiocytic sarcoma following combination chemotherapy for a primary mediastinal germ cell tumor in a 26-year-old Asian man who visited the General Medicine Department of a hospital with complaints of cough and high fever. Chest computed tomography (CT) imaging revealed a tumor (diameter 10.5 cm) in the anterior mediastinum, with no signs of metastasis, and CT-guided biopsy of the mediastinal tumor revealed the presence of some necrotic cartilages. The patient’s serum α-fetoprotein (AFP) level was determined to be high at 160.4 ng/mL and a primary mediastinal non-seminomatous germ cell tumor was suspected, so the patient was referred to the Department of Urology. Despite the presence of severe thrombocytopenia, the patient was treated using a combination of chemotherapy and intermittent transfusion, which was able to normalize his serum AFP level. However, resection of the mediastinal tumor was unsuccessful due to persistent thrombocytopenia and the patient was subsequently transferred to our hospital for further examination and treatment. Despite management by hematologists, the condition of the patient did not improve; although his AFP level remained normal, the tumor increased in size and then metastasized to the liver and spleen. The general condition of the patient deteriorated and he died 9 months after his first visit. The patient was diagnosed with histiocytic sarcoma following a pathological autopsy. Due to the extremely rare incidence of histiocytic sarcoma, this condition should be a differential diagnosis and the appropriate tests must be conducted to give an exact treatment.
Literatur
1.
Zurück zum Zitat Moch H et al (eds) (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC Press, Lyon Moch H et al (eds) (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC Press, Lyon
2.
Zurück zum Zitat Pileri SA, Grogan TM, Harris NL et al (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRef Pileri SA, Grogan TM, Harris NL et al (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRef
3.
Zurück zum Zitat Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRef Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRef
4.
Zurück zum Zitat Song SY, Ko YH, Ahn G (2005) Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol 13:299–303CrossRef Song SY, Ko YH, Ahn G (2005) Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol 13:299–303CrossRef
5.
Zurück zum Zitat Sohn BS, Kim T, Kim JE et al (2010) A case of histiocytic sarcoma presenting with primary bone marrow involvement. J Korean Med Sci 25:313–316CrossRef Sohn BS, Kim T, Kim JE et al (2010) A case of histiocytic sarcoma presenting with primary bone marrow involvement. J Korean Med Sci 25:313–316CrossRef
6.
Zurück zum Zitat Sood R, Mehta A, Bansal D et al (2019) Mediastinal mixed germ cell tumor with splenic histiocytosis: a rare coincidence. Indian J Pathol Microbiol 62:341–342CrossRef Sood R, Mehta A, Bansal D et al (2019) Mediastinal mixed germ cell tumor with splenic histiocytosis: a rare coincidence. Indian J Pathol Microbiol 62:341–342CrossRef
7.
Zurück zum Zitat Shinoda H, Yoshida A, Teruya-Feldstein J (2009) Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor. Appl Immunohistochem Mol Morphol 17:338–344CrossRef Shinoda H, Yoshida A, Teruya-Feldstein J (2009) Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor. Appl Immunohistochem Mol Morphol 17:338–344CrossRef
8.
Zurück zum Zitat Fang LH, Shih LS, Lee PI et al (2016) Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: a case report. Medicine 95:e2515CrossRef Fang LH, Shih LS, Lee PI et al (2016) Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: a case report. Medicine 95:e2515CrossRef
9.
Zurück zum Zitat Go H, Jeon YK, Huh J et al (2014) Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRef Go H, Jeon YK, Huh J et al (2014) Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRef
10.
Zurück zum Zitat Michonneau D, Kaltenbach S, Derrieux C et al (2014) BRAF V600E mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRef Michonneau D, Kaltenbach S, Derrieux C et al (2014) BRAF V600E mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRef
11.
Zurück zum Zitat Idbaih A, Mokhtari K, Emile J-F et al (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRef Idbaih A, Mokhtari K, Emile J-F et al (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRef
12.
Zurück zum Zitat Branco B, Comont T, Ysebaert L et al (2019) Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature. Eur J Haematol 103:444–448CrossRef Branco B, Comont T, Ysebaert L et al (2019) Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature. Eur J Haematol 103:444–448CrossRef
13.
Zurück zum Zitat Diamond EL, Subbiah V, Lockhart AC et al (2018) Vemurafenib for BRAF V600–mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384–388CrossRef Diamond EL, Subbiah V, Lockhart AC et al (2018) Vemurafenib for BRAF V600–mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384–388CrossRef
Metadaten
Titel
Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma
verfasst von
Hiroshi Yaegashi
Yuki Kato
Takahiro Nohara
Kouji Izumi
Yoshifumi Kadono
Tohru Miyagi
Takao Nakashima
Kaori Yoshimura
Yasunori Sato
Kenichi Harada
Atsushi Mizokami
Publikationsdatum
09.01.2021
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 2/2021
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-020-00467-7

Weitere Artikel der Ausgabe 2/2021

International Cancer Conference Journal 2/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.